<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580695</url>
  </required_header>
  <id_info>
    <org_study_id>C4COA01</org_study_id>
    <nct_id>NCT02580695</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee Osteoarthritis</brief_title>
  <official_title>A Phase I/II, Randomized, Double-blind, Controlled Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UC-MSCs) in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francisco Espinoza, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Los Andes, Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knee-osteoarthritis (OA) is a common and disabling problem, that represents a global health
      issue since none of the current therapies are truly disease modifying. The use of mesenchymal
      stem cells (MSCs) in OA-preclinical models has been associated with a reduction in cartilage
      degradation, the attenuation of bone sclerosis and an effective anti-inflammatory response.
      Investigators have designed a randomized phase I/II placebo controlled trial of UC-MSCs in
      knee OA. Outcomes will be evaluated at 12 months, comparing monodosis versus double
      intra-articular injection, re-randomized at 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who experience an adverse event</measure>
    <time_frame>12 months</time_frame>
    <description>according to National Cancer Institute Common Terminology Criteria for Adverse Effects (NCI-CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical function improvement measured by WOMAC OA index</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain density measured by Visual analogue scale (VAS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL improvement measured by SF-36</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in WORMS scale measured by knee MRI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Umbilical-cord mesenchymal stromal cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical-cord mesenchymal stromal cells (UC-MSCs)
Allogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB
Arm 2a: single infusion group. UC-MSCs at 0 month
Arm 2b: double infusion group. UC-MSCs at 0 and 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid (HA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>umbilical-cord mesenchymal stromal cells</intervention_name>
    <description>Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months</description>
    <arm_group_label>Umbilical-cord mesenchymal stromal cells</arm_group_label>
    <other_name>UC-MSCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months</description>
    <arm_group_label>Hyaluronic Acid (HA)</arm_group_label>
    <other_name>Durolane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic Knee OA, Kellgren and Lawrence grade I, II, III on plain Rx films.

          -  Chondromalacia patella grade I-III on knee MRI. With or without meniscal tear.

          -  Stable knee and normal clinical exam of involved extremity

          -  Written informed consent for patients.

        Exclusion Criteria:

          -  Bilateral symptomatic knee OA

          -  Local or systemic infection.

          -  Active neoplasia or immunosuppressive state

          -  Pregnancy or Breastfeeding

          -  Body Mass Index â‰¥ 30

          -  Presence of Pacemaker or Lower extremity metal implant

          -  Anticoagulant treatment other than aspirin.

          -  Recent use of oral (previous month) or intra-articular (previous 3 months)
             corticosteroids

          -  Concomitant inflammatory joint disease (cristal, connective tissue disease)

          -  Valgus (&gt;10o) or Varus (&gt;5o) deformity of involved extremity

          -  Condilar or Tibial plateau Generalized Bone Marrow edema on MRI

          -  Significant symptomatic hip or spine disease

          -  Significant abnormality in baseline lab tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Matas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de los Andes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universidad de los Andes</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Los Andes, Chile</investigator_affiliation>
    <investigator_full_name>Francisco Espinoza, MD</investigator_full_name>
    <investigator_title>Alternative Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

